Quantifying Synergy for Combination Drug Studies
*John Joseph Peterson, GlaxoSmithKline Pharmaceuticals 


Combination drug therapies offer much promise for treating cancer, infectious diseases, and other diseases involving multiple cellular pathways. However, until now a truly general approach to quantifying “drug synergy” has not been available in the biomedical literature. This roundtable will provide a brief overview of classical measures of drug synergy and their drawbacks, and also discuss a new quantitative approach based upon mixture experiments.